Glycogen storage disease type III screening: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Glycogen storage disease type III}} {{CMG}}; {{AE}} ==Overview== There is insufficient evidence to recommend routine screening for [disease/malignancy]. OR Ac...") |
No edit summary |
||
Line 4: | Line 4: | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} | ||
==Overview== | ==Overview== | ||
Glycogen storage disease type 3 is an [[autosomal recessive]] disease so [[carrier]] [[Screening (medicine)|screening]] of at-risk relatives may be done. [[Screening (medicine)|Screening]] requires prior identification of AGL [[pathogenic]] variants in the family. | |||
==Screening== | ==Screening== | ||
*Glycogen storage disease type 3 is an [[autosomal recessive]] disease. | |||
* | *[[Carrier]] [[Screening (medicine)|screening]] of at-risk relatives may be done. | ||
*[[Screening (medicine)|Screening]] requires prior identification of AGL [[pathogenic]] variants in the family. | |||
* | |||
* | |||
==References== | ==References== |
Revision as of 15:53, 18 December 2017
Glycogen storage disease type III Microchapters |
Differentiating Glycogen storage disease type III from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type III screening On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type III screening |
Risk calculators and risk factors for Glycogen storage disease type III screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Glycogen storage disease type 3 is an autosomal recessive disease so carrier screening of at-risk relatives may be done. Screening requires prior identification of AGL pathogenic variants in the family.
Screening
- Glycogen storage disease type 3 is an autosomal recessive disease.
- Carrier screening of at-risk relatives may be done.
- Screening requires prior identification of AGL pathogenic variants in the family.